Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.

ABSTRACT:

Background

Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp.

Methods

This double-blind, randomized, crossover active-controlled trial compared 2-h postprandial plasma glucose (PPG) response, following 2 weeks of CSII with faster aspart or IAsp. Primary endpoint: mean change in PPG 2 h after a standardized meal test (ΔPG_av,0-2h). Subjects (n = 43) had masked continuous glucose monitoring (CGM) throughout.

Results

Faster aspart provided a statistically significantly greater glucose-lowering effect following the meal versus IAsp: ΔPG_av,0-2h: 3.03 mmol/L versus 4.02 mmol/L (54.6

SUBMITTER: Bode BW 

PROVIDER: S-EPMC5248540 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature